



Universiteit  
Leiden  
The Netherlands

## **Guide to the heart: Differentiation of human pluripotent stem cells towards multiple cardiac subtypes**

Schwach, V.

### **Citation**

Schwach, V. (2020, January 15). *Guide to the heart: Differentiation of human pluripotent stem cells towards multiple cardiac subtypes*. Retrieved from <https://hdl.handle.net/1887/82699>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/82699>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden





The handle <http://hdl.handle.net/1887/82699> holds various files of this Leiden University dissertation.

**Author:** Schwach, V.

**Title:** Guide to the heart: Differentiation of human pluripotent stem cells towards multiple cardiac subtypes

**Issue Date:** 2020-01-15





## Chapter 7:

# Native cardiac environment and its impact on engineering cardiac tissue

Verena Schwach<sup>1</sup> and Robert Passier<sup>1, 2</sup>

<sup>1</sup>Dept of Anatomy and Embryology, Leiden University Medical Center, The Netherlands; <sup>2</sup>Dept of Applied Stem Cell Technologies, TechMed Centre, University of Twente, The Netherlands

*Biomaterials Science* 7 (9): 3566-3580 (2019)



### **Abstract**

Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) generally have an immature fetal-like phenotype when directly compared to isolated CMs from human hearts, despite significant advance in differentiation of human pluripotent stem cells (hPSCs) to multiple cardiac lineages. Therefore, hPSC-CMs may not accurately mimic all facets of healthy and diseased human adult CMs. During embryonic development, the cardiac extracellular matrix (ECM) experiences a gradual assembly of matrix proteins that transits along the maturation of CMs. Mimicking these dynamic stages may contribute to hPSC-CMs maturation *in vitro*. Thus, in this review, we describe the progressive build-up of the cardiac ECM during embryonic development, the ECM of the adult human heart and the application of natural and synthetic biomaterials for cardiac tissue engineering with hPSC-CMs.

## Introduction

Since the first isolation of human pluripotent stem cells (hPSCs), their remarkable capacity to self-replicate and differentiate into every cell type of the human body aroused great interest and has advanced the fields of human disease modeling and pre-clinical pharmacology. Particularly because of the limited regenerative capacity of the human heart, as well as the difficulty to propagate primary cardiomyocytes (CMs) *in vitro*, hPSC-derived CMs (hPSC-CMs) are increasingly acknowledged as an alternative and accessible cell source for disease modeling, as well as drug and safety pharmacology or regenerative cardiac repair (Braam et al., 2010; Caspi et al., 2009; Chong et al., 2014; Doherty et al., 2015; Himmel, 2013; van Laake et al., 2007; Laflamme et al., 2007; Liang et al., 2010, 2013; Navarrete et al., 2013; Sharma et al., 2014; Shiba et al., 2016; Shinozawa et al., 2012; Stancescu et al., 2015; Talbert et al., 2015). Protocols to generate distinct cellular subtypes of the human heart, which include ventricular (BurrIDGE et al., 2014; Mummery et al., 2012), atrial (Devalla et al., 2015; Laksman et al., 2017; Pei et al., 2017; Schwach et al., 2017) and pacemaker CMs (Birket et al., 2015; Protze et al., 2016), as well as epicardial cells and epicardial-derived smooth muscle cells and fibroblasts (Guadix et al., 2017; Iyer et al., 2015; Witty et al., 2014) and endothelial cells (Giacomelli et al., 2017; Orlova et al., 2014) have been developed and are continuously optimized. Despite these significant advances in directing differentiation to multiple cardiac lineages, hPSC-CMs are generally characterized by an immature fetal-like phenotype and may therefore not accurately mimic all facets of healthy and diseased human adult CMs. In a direct comparison to human hearts, gene expression patterns and morphological and functional characteristics of hPSC-CMs resemble that of fetal hearts (Table 7.1) (van den Berg et al., 2015; Braam et al., 2010; Nunes et al., 2013; Ribeiro et al., 2015). For a detailed overview about the immaturity of hPSC-CMs, we refer to other comprehensive reviews on this topic (Denning et al., 2016; Robertson et al., 2013; Veerman et al., 2015; Yang et al., 2014).




**Table 7.1:** Properties of fetal and adult CMs (Adapted from (Denning et al., 2016; Yang et al., 2014).

|   |  | <b>Immature fetal CMs</b>                    | <b>Mature adult CMs</b>                |
|---|--|--|--|
| <b>Morphology</b>                           | Cell morphology                              | Circular                                     | Rod-shaped                             |
|   | Sarcomere morphology                         | Disorganized                                 | Highly organized                       |
|   | Sarcomere length                             | ~ 1.6 $\mu\text{m}$                          | ~ 2.2 $\mu\text{m}$                    |
|   | T-tubules                                    | -  | Yes                                    |
|   | Nucleation                                   | Mostly mono-nucleated                        | 25 – 30% bi – or polynucleated         |
| <b>Mechanical parameters</b>                | Contractile force                            | ~ nN for single cells                        | ~ $\mu\text{N}$ for single cells       |
|   | 0.08 - 4 mN/mm <sup>2</sup> 3D tissues       | ~ $\mu\text{N}$ for single cells             | 0.08 - 4 mN/mm <sup>2</sup> 3D tissues |
|   | <b>40 - 80 mN/mm<sup>2</sup> 3D tissues</b>  |  |  |
|   | Conduction velocity                          | ~ 0.1 - 0.2 m/s                              | 0.3 - 1 m/s                            |
| <b>Expression</b>                           | Isoform expression                           | MYH6 ( $\alpha$ -MHC) > MYH7 ( $\beta$ -MHC) |  |
| <b>MYL2 (MLC2v) : MYL7 (MLC2a)</b>          |  |  |  |
| <b>TNNI (fetal ssTnI) &gt; TNNI3 (cTnI)</b> | MYH7 ( $\beta$ -MHC) > MYH6 ( $\alpha$ -MHC) |  |  |
| <b>MYL2 (MLC2v) &gt; MYL7 (MLC2a)</b>       |  |  |  |
| <b>TNNI3 (cTnI) &gt; TNNI (fetal ssTnI)</b> |  |  |  |
|   | Gap junctions                                | Circumferential                              | Polarized to intercalated discs        |
| <b>Electrophysiological parameters</b>      | Upstroke velocity                            | 10 - 50 V/s                                  | 150 - 350 V/s                          |
|   | Resting membrane potential                   | -20 - 60 mV                                  | -80 - 90 mV                            |

Various strategies have been applied to enhance maturity of hPSC-CMs *in vitro*, including prolonged time in culture, electrical or mechanical stimulation, addition of chemical or biological factors, co-culture with non-CMs, three-dimensional (3D) assembly into tissues and the use of specific scaffold materials (Figure 7.1) (Sun and Nunes, 2017; Veerman et al., 2015; Yang et al., 2014). Despite distinct improvements - those strategies often only induce some aspects attributed to cardiac maturity - hPSC-CMs

never acquired an adult cardiac phenotype. Therefore, further progress necessitates the development of more advanced models, as for example engineering 3D cardiac tissue surrogates closely resembling the native cardiac microenvironment.



**Figure 7.1:** Strategies to enhance the maturity level of hPSC-CMs.

In this review, we describe the expression of extracellular matrix (ECM) proteins in the native microenvironment of human CMs with focus on developmental changes and respect to different heart compartments, such as atria and ventricles and also the right and left side of the heart. Moreover, we discuss the application of natural and synthetic biomaterials in the context of *in vitro* cardiac tissue engineering with hPSC-CMs and their effect on hPSC-CM maturity.

## The native environment of CMs

Cells in their native environment are embedded within a network of ECM components, which are crucial for proper development and function of tissues and organs. The ECM delivers vital cues for various cellular responses, which include fate determination, migration, proliferation, morphology, cell






arrangement, survival and maturation. The cardiac ECM additionally needs to provide a strong support and elastic anchorage for precisely aligned CMs and creates a specialized environment to permit electrical coupling and cardiac impulse propagation between adjacent cells and transmission of contractile forces of CMs to the surrounding matrix for the repetitive blood pumping function of the heart (Chen et al., 2014; Heras-Bautista et al., 2014; Kléber and Rudy, 2004; Marijianowski et al., 1994; McCain et al., 2014). The basic structural unit of the cardiac ECM is primarily composed of collagen, but also includes laminin, fibronectin, fibrillin and elastin, which are continuously secreted by different cell types and assembled into a hierarchically organized scaffold (Table 7.2 and Figure 7.2) (Bishop and Laurent, 1995).

**Table 7.2:** Selection of proteins of the ECM in the heart

|                              | <b>Expression</b>   | <b>Structure</b>  | <b>Function</b>  | <b>Secreted by:</b>                      |
|------------------------------|---|---|--|--|
| <b>Collagen I</b>            | Extra- and intracellularly in all tissues, but not in basement membrane         | Triple-helical fibrils from fibrillary collagen   | Structural support and strength                                    | Fibroblasts                              |
| <b>Collagen III</b>          | Extra- and intracellularly in all tissues, but not in basement membrane         | Triple-helical fibrils from fibrillary collagen   | Structural support and elasticity                                  | Fibroblasts and smooth muscle cells      |
| <b>Collagen IV</b>           | Predominant protein in basement membrane  | Rope-like, very long fibrils and sheet-like network   | Cell-ECM interaction, connection to other ECM proteins             | Fibroblasts, smooth muscle cells and CMs |
| <b>Collagen VI</b>           | Extracellularly in all tissues, but not in basement membrane or intracellularly | Fine filaments in 90° orientation to other collagens  | Adhesion and migration of cells, connection to other ECM proteins  | Fibroblasts and smooth muscle cells      |
| <b>Fibronectin</b>           | Extra- and intracellularly in all tissues and plasma                            | Two chains connected by disulfide bridges. Dimers connect into fibrils only via integrin receptors on cell surfaces | Cell-ECM interaction via cell surface receptors, such as integrins | Fibroblasts and smooth muscle cells      |
| <b>Laminin</b>               | Most prominent glycoprotein in basement membrane                                | Self-assemble into asymmetric planar sheets   | Cell-ECM interaction via cell surface receptors, such as integrins | Fibroblasts, smooth muscle cells and CMs |
| <b>Elastin and fibrillin</b> | Extracellularly   | Long, very hydrophobic protein. No stretch: Circular compact Stretch: elongated interconnected strains              | Elasticity   | Fibroblasts and smooth muscle cells      |



**Figure 7.2:** Most common ECM proteins in the heart.

Fibrillary collagens type I and type III form a complex fiber scaffold composed of thicker collagen I and thinner collagen III triple helical fibrils that have interconnected into larger fibers (fibril diameter depends on the tissue: in adult healthy cardiac tissue collagen I fibril diameter varies around 75 nm and collagen III fibrils around 45 nm (de Souza, 2002)). Thicker collagen I fibers are important to convey the necessary rigidity and stability, while collagen III fibers support the elasticity of the cardiac ECM (Marijjanowski et al., 1994). Additional elastic flexibility of the cardiac wall is regulated by distribution and content of interspersed elastic fibers. Elastic fibers are primarily made from microfibrillary fibrillin with amorphous elastin as core protein (Votteler et al., 2013). Together with collagen type IV, laminin has a key role in linking CMs to their surrounding ECM and serves as cell adhesive protein. (Kim et al., 1999; Speiser et al., 1991, 1992). Similarly, fibronectin anchors cells to the ECM and transduces extracellular signaling to mediate cellular response (Farhadian et al., 1996). In mice, knockout of fibronectin has been shown to result in differentiation of cardiac progenitors towards CMs while inhibiting proliferation of cardiac progenitor cells in the pre-cardiac mesoderm during cardiac morphogenesis (Mittal et al., 2013). Another key component of the ECM are glycosaminoglycans, which interact with several signaling molecules to regulate differentiation, protection against oxidative stress and also cardiac remodeling after injury (Rienks et al., 2014). In human left and right atrial and ventricular walls, five different glycosaminoglycans have been identified: hyaluronic acid, heparan sulfate, dermatan sulfate, chondroitin-4-sulfate and chondroitin-6-sulfate (Masuda and Smcmjo, 1981; Shichijo and Masuda, 1980).

Most ECM proteins interact with cells via transmembrane receptors, so-called integrins, which do not only function as principal anchor for the cells to their surrounding ECM, but also mediate bi-directional communication



across the membrane to regulate cellular behavior via ligand binding on the outside (outside-in), or receptor activity by intracellular signaling (inside-out signaling). In the heart, integrins are also linked to the cytoskeletal protein alpha-actinin via talin and vinculin, thereby transmitting the mechanical forces from the inside of CMs to the ECM (Legate et al., 2009; Shen et al., 2012).

### Native cardiac ECM during human heart development

Composition of the ECM is dynamic throughout embryonic development and adulthood, thereby providing stage-dependent clues for maturation of CMs (Figure 7.3).

Early during heart development, around the end of the first trimester of human development, laminin, fibronectin and most collagen fibers predominantly localize along the endocardial and epicardial layers (Jackson et al., 1993; Kim et al., 1999) CMs within the myocardium are supported by a premature collagen network primarily build from thin, loose fibers of collagen type III only (Jackson et al., 1993).

At the beginning of the second trimester with the onset of increased fetal growth and higher energy demands in the embryo, fibronectin and notably laminin become more widely distributed and strongly expressed within the myocardium (Kim et al., 1999; Speiser et al., 1992). Laminin is particularly expressed in the basal membrane of CMs, but also smooth muscle and capillary endothelial cells (Speiser et al., 1991). The basal membrane is a dense, highly organized layer that connects each cell with their surrounding ECM. Laminins are heteromerically formed by cell subtype-specific structural subchains, e.g. the A1-chain is primarily present in the basal membrane of vascular cells and not CMs, whereas the A2-chain is only present around CMs (Kim et al., 1999; Oliviero et al., 2000; Saetersdal et al., 1992; Speiser et al., 1992). Fibronectin is predominantly localized around blood vessels close to smooth muscle cells and the basal membrane of fibroblasts and along endo- and epicardial layers (Kim et al., 1999; Oliviero et al., 2000; Saetersdal et al., 1992; Speiser et al., 1992). Along with progressive build-up of the ECM, collagen fiber thickness increases and the premature collagen network quickly develops into a highly aligned, interconnected and

intercoiled network with similar ratios of collagen type I and III, or at the most a small shift in favor of collagen I (Jackson et al., 1993; Marijjanowski et al., 1994; Speiser et al., 1991).

Postnatally, laminin strands have interconnected and built a fine, complex fibrillary network throughout the myocardium (Kim et al., 1999; Oliviero et al., 2000; Saetersdal et al., 1992; Speiser et al., 1992). Despite no differences in total laminin, cardiac A2-laminin, fibronectin and total collagen proportions decrease immediately after birth, leading to a reduction of approximately 50% in the adult heart (Kim et al., 1999; Marijjanowski et al., 1994; Oliviero et al., 2000).

Less attention has been paid to the expression and distribution of less prominent collagens, such as collagen type IV and VI, as well as fibrillin and elastin in human myocardium during development. Moreover, little is known about expression of fibronectin isoforms in human fetal or adult cardiac tissues. However, in the mouse heart, three different isoforms of highly conserved fibronectin are generated by alternative splicing. Domains A and B, but not C of fibronectin are specifically expressed during embryonic development of the heart, but not in adult stages (Lu et al., 2015).

### Native ECM in adult heart

In adulthood, collagen type III is twice more abundant than collagen type I (Marijjanowski et al., 1994; Speiser et al., 1991). It is important to note that collagen is not evenly distributed throughout the adult heart, most of the collagen resides in the endo- and epicardium with a dense, thick subendocardial network, which gradually changes to a thinner subepicardial network. Similarly a dense, thick network of collagen fibrils can be observed at the base of the heart, close to the atrioventricular valves below the papillary muscles, which gradually declines in thickness in the direction of the apex of the heart (Jackson et al., 1993). In conjunction with lower atrial pressures and less compliant atrial compared to ventricular muscle, collagen I and III are twice more abundant in the myocardium of both atria than ventricles (Oken and Boucek, 1957; Smorodinova et al., 2015). Similarly, collagen I and III content is higher in the right heart compared to the left (Oken and Boucek, 1957; Smorodinova et al., 2015). In contrast



## Chapter 7

to intraventricular differences which are already obvious during the first trimester of human development (Jackson et al., 1993), differences in collagen expression between heart chambers only become apparent after birth, coinciding with the first respiration of the newborn and transition to independent systemic circulation resulting in pressure differences between the four cardiac chambers (Oken and Boucek, 1957).

In adult hearts, collagen VI has an overlapping expression pattern with collagen I and III, although fibers are much finer. To assemble into a complex fibrillary network, collagen VI fibers orientate in perpendicular orientation to collagen I and III (Speiser et al., 1991). Collagen IV is the only collagen secreted by CMs and the majority of collagen IV associates with laminin and fibronectin in the basal membrane of single atrial or ventricular CMs (Bashey et al., 1992; Borg et al., 1982; Jiang et al., 2016; Speiser et al., 1991). In human adult ventricular myocardium, collagen IV, laminin and fibronectin span the inner lining of the t-tubular network, thereby preventing collapse of t-tubules during cardiac contraction (Kim et al., 1999; Speiser et al., 1991, 1992). In the adult heart, elastin fibers assemble into an irregular network with fibers parallel to the long axis of muscle fibers. Importantly, not only the elastin content, but also fiber length is at least twice as long in the ECM of the right atria and ventricle compared to that of the left heart compartments (de Carvalho Filho et al., 1996; Smorodinova et al., 2015). Moreover, as opposed to irregular, less interconnected and more circular elastin in the left atrium, straight, parallel elastic fiber strands interconnect into a highly organized fibrillary scaffold in the right atrium (Smorodinova et al., 2015). Differences between right and left atrium might be due to diverse biomechanical stimulation of cardiac fibroblasts or different cell origins, but need further investigation for clarification (Smorodinova et al., 2015).


With increasing age the ratio of thick, densely packed collagen and elastin fibers increase in all chambers of the heart, but predominantly in the left ventricle (Alings et al., 1995; de Carvalho Filho et al., 1996; Gazoti Debessa et al., 2001).

The sinoatrial node is a specialized region in the posterior wall of the right atrium responsible for the initiation of the electrical impulse during each cardiac contraction cycle. The uniformly distributed bundles of collagen fibers are only sparsely dispersed within the human sinoatrial node during embryonic development, but comprise about 40% of the entire nodal

volume after birth and up to ~70% in adult hearts to form a dense regular framework. In rats, fibroblasts in the sinoatrial node predominantly secrete collagen I and III (Yanni et al., 2010), but it is not confirmed which collagens predominate in the human sinoatrial node. The collagen network of the sinoatrial node, is key to the mechanical support of nodal CMs, which rely on extra support because of their underdeveloped contractile machinery when compared to CMs of the working myocardium. The dense collagen network, which isolates groups of sinus node cells plays a negative role in maturation by limiting contact between groups of sinoatrial CMs, as well as sinoatrial CMs and their adjacent atrial CMs (Alings et al., 1995; James, 1970; Nabipour, 2012). In combination with fatty tissues, collagen may also be important in insulating pacemaker automaticity from surrounding atrial CMs (Csepe et al., 2015).

Matrix changes have not only been associated with cardiac development, but also various cardiac diseases. Post myocardial infarction (MI) around the infarct zone or in fibrotic scar tissue of hearts with cardiomyopathy, not only enhanced deposition of collagen type I, but also III, IV and VI, as well as fibronectin and laminin has been observed (Bishop et al., 1990; Kapelko, 2001; Kitamura et al., 2001; Lombardi et al., 2003; Ma et al., 2014; Oken and Boucek, 1957; Pauschinger et al., 1999). Interestingly, also permanent atrial fibrillation leads to an increase in collagen I, III and IV in both atria (Boldt et al., 2004; Jiang et al., 2016). No gender differences in collagen content or distribution have been detected during development or later (Alings et al., 1995; Marijianowski et al., 1994; Oken and Boucek, 1957).





**Figure 7.3:** Upper panel: Schematic representation of the dynamic changes of the expression of ECM proteins in the heart. During the first trimester, the ECM network is primarily composed of collagen III. Laminin and fibronectin localize to endo- and epicardial layers. In the second trimester, collagen I, as well as laminin and fibronectin become more widely expressed and collagen fiber thickness increases. The premature collagen network develops into a highly organized network. In postnatal and adult hearts, laminin strands have interconnected to form a complex fibrillary network. Collagen III is now twice more abundant than collagen type I. Additionally, collagen I and III are twice more abundant in the myocardium of both atria than ventricles and collagen I and III amounts are higher in the right heart compared to the left. With increasing age the ratio of thick, densely packed collagen, as well as the fiber thickness increase. Lower panel: Schematic representation of the ECM changes in the diseased heart. Post myocardial infarction around the infarct zone (marked in red in left ventricle) or in fibrotic scar tissue in cardiomyopathy (see left ventricle), enhanced deposition of collagen type I, III, IV and VI, as well as fibronectin and laminin has been observed. Similarly, permanent atrial fibrillation leads to an increase in collagen I, III and IV in both atria.

## Natural and synthetic biomaterials

Although a variety of biomaterials have been used for tissue-engineering replacements for different tissues, including bone, cartilage, tendon or skin, lungs and bladder (Shapira-Schweitzer et al., 2009), the ability to utilize natural or synthetic biomaterials for cardiac repair has proven more challenging than originally anticipated.

The use of natural biomaterials for engineering of tissue constructs shows many obvious benefits for mimicking endogenous tissues and organs. Nonetheless, important drawbacks of natural materials are their limited availability and shelf life, as well as batch-to-batch variation and high costs. Even more importantly, reproducible scaffold design from pure natural materials often can be challenging. Alternatively, synthetic polymers have adjustable mechanical and degradation properties and unlimited availability. Nevertheless, in contrast to natural biomaterials, synthetic materials have reduced biocompatibility and may provoke adverse rejection responses. Especially for the *in vitro* generation of soft tissue, such as mechanically challenging cardiac tissue, only few synthetic materials with appropriate combination of biodegradability, biocompatibility and mechanical properties without compromising cellular function of CMs have been applied so far (O'Brien, 2011; Patel et al., 2015; Shapira-Schweitzer et al., 2009). Selection of natural and synthetic biomaterials for cardiac tissue engineering are presented in Table 7.3 and Table 7.4, respectively.



**Table 7.3:** Selection of natural polymers

|          | Structure                | Origin   | Properties  |
|----------|--------------------------|--|---|
| Gelatin  | Fine fibrillary scaffold | Hydrolysis of collagen   | Deforms rapidly, low tensile strength, rapidly bioresorbable, |
| Matrigel | Hydrogel                 | Secretion by mouse sarcoma cells: Laminin, collagen IV, heparin sulfate proteoglycans, entactin/nidogen    | Resistance against remodeling                                 |
| Fibrin   | Fibrillary scaffold      | Plasma-glycoprotein, for blood clotting Fibrinogen as precursor for blood clotting Fibrinogen as precursor | Tunable properties and quickly remodeled                      |



**Table 7.4:** Selection of synthetic polymers

|               |  | Approval for clinical application | Application                           |
|---------------|--|-----------------------------------|---------------------------------------|
| Poly-esters   | Poly-glycolic acid (PGA)                     | Approved by the FDA               | Re-absorbable suture material         |
|               | Poly-lactic acid (PLA)                       | Approved by the FDA               | Rigid thermoplastic materials         |
|               | Co-polymers poly-lactic-glycolic acid (PLGA) | Approved by the FDA               | Scaffold for controlled drug release  |
| Poly-lactones | Poly-caprolactone (PCL)                      | Approved by the FDA               | Implantable drug delivery             |
|               | Carboxylated-PCL (cPCL)                      |                                   |                                       |
| Elastomers    | Poly-dimethyl-siloxane (PDMS)                | Approved by the FDA               | Medical devices                       |
|               | Poly-glycerol sebacate (PGS)                 | Approved by the FDA               | Nerve and vascular tissue engineering |
| PEG           | Poly-ethylene glycol                         | Approved by the FDA               | PEGylated drugs                       |

**Desired biomaterial properties for cardiac tissue engineering and *in vitro* modeling of hPSC-CMs**

CMs display a high sensitivity to environmental factors, such as elasticity, geometry and topography (Farouz et al., 2015; Nakane et al., 2017) and extracellular substrates have already been shown to induce some aspects of cardiac maturity (Sun and Nunes, 2017; Veerman et al., 2015). In order to emulate the native cardiac environment, the preferred biomaterial needs to meet the following essential criteria:

- 1) Long-term elasticity and mechanical strength (suitable stiffness) to sustain the high repetitive mechanical stress and non-linear elasticity of contracting muscle
- 2) Adaptable biodegradability long enough to facilitate cell attachment and bear the proteolytic activity of diseased myocardium, while avoiding a persisting response against a foreign structure
- 3) Biocompatibility that is not toxic for the cells and supports cell survival

- 4) Structural facilitation of neovascularization and remodeling
- 5) Controllable electrical properties that do not interfere with the electrical conductance of the action potential
- 6) Outside-in-signaling enabling optimal CM attachment, survival, growth, maturation and function *in vitro*, and support of functional cardiac contraction and integration into the host tissue after implantation *in vivo*

### **Scaffold-mediated engineered cardiac tissues**

Natural materials as ECM and multicellular approaches in human cardiac tissues engineered from hPSC-CMs

To generate cardiac tissues which include the natural ECM components in a developmentally and physiologically relevant organization, approaches have been undertaken to decellularize cardiac tissue, resulting in a 3D cell-free cardiac ECM meshwork, followed by repopulation with cardiac cells or their progenitors in order to study processes like survival, migration, proliferation, maturation and communication. Repopulation of a decellularized mouse heart with hPSC-derived  $KDR_{low}/C-KIT_{neg}$  cardiovascular progenitor cells (CPCs) with the capacity to differentiate into CMs, smooth muscle cells and endothelial cells allowed formation of a bioartificial heart suitable for analyzing ECG traces, contraction and drug response (Lu et al., 2013). Here, stable interaction between the ECM of the decellularized heart allowed about 10-15% of the CPCs to be retained in the natural cardiac ECM meshwork. These CPCs formed a revascularized spontaneously beating tissue within 20 days after repopulation. Interestingly, endothelial cells formed a single layer along the endocardial surface, as well as the inner surface of small coronary vessels suggesting that the natural ECM effectively supported correct arrangement of *in situ* differentiated cardiac cells. Although these studies indicate the importance of a natural scaffold of ECM components for the formation of 3D cardiac tissue, alternative strategies are required for controlled production of cardiac tissues, since material source is limited and morphology is difficult to adjust to the desired shape of the tissue. Instead of using a complex ECM network, many approaches for generation of cardiac tissues are based on only a few components or a mixture thereof.



Several features attributed to maturation of hPSC-CMs have been achieved in engineered 3D human cardiac tissues utilizing fibrin in combination with matrigel, a mixture of laminin together with collagen IV and proteoglycan derived from mouse sarcoma cells, as ECM material (Hirt et al., 2014; Mannhardt et al., 2015; Schaaf et al., 2011; Stoehr et al., 2014; Zhang et al., 2013, 2017). Fibrin is an insoluble fibrous protein, involved in blood clotting and wound healing, with little presence in the healthy fetal or adult heart. Instead, increased plasma levels of fibrin have been acknowledged as important cardiovascular risk factor (Stec et al., 2000). However, practical reasons, such as tunable physical and mechanical properties, as well as biodegradability, made fibrin the protein of choice for tissue engineering. Consistent with enhanced expression of genes important for cardiac contractile function and calcium handling, sarcomeres in cardiac tissues with fibrin as scaffold material were highly organized and evenly distributed with a longitudinal orientation along force lines and enhanced sarcomere length of approximately 1.6  $\mu\text{m}$  (Mannhardt et al., 2015) and 2.1  $\mu\text{m}$  (Zhang et al., 2013). Structural maturation led to a sustained contraction force of  $\sim 0.15$  mN (Mannhardt et al., 2015) or  $\sim 3$  mN (Zhang et al., 2013) and higher conduction velocities (10 cm/s up to 25 cm/s with increased hPSC-CM purity)(Zhang et al., 2013). Interestingly, hPSC-CMs in heterogeneous cardiac tissues, typically consisting of hPSC-CMs mixed with fibroblasts and other non-CMs, developed immature t-tubular-like structures (Mannhardt et al., 2015). T-tubules are a manifestation of CM maturation typically absent in hPSC-CMs. However, as evidenced by metabolic phenotype, sarcomeric organization, intercellular connection, electrical function and low sensitivity to calcium, 3D cardiac tissues failed to induce full maturation. Continuous electrical pacing (Hirt et al., 2014) or mechanical load (Zhang et al., 2017) by stretching had additive positive effect on CM morphology, as proven by sarcomeric organization, transcriptional profile and contraction force. Recently, it was shown that physical conditioning by electromechanical stimulation of early-stage hPSC-derived CMs in fibrin hydrogel cardiac tissues with supporting dermal fibroblasts induced maturation to an adult-like stage regarding gene expression, ultrastructural organization, such as physiological sarcomere length of 2.2  $\mu\text{m}$ , presence of mitochondria and t-tubules, as well as oxidative metabolism, positive force–frequency relationship and functional calcium handling. However, electromechanics did not reach maturity seen in adult human myocardium (Ronaldson et al., 2018).

Since fibrin only has a minor role in the cardiac ECM and therefore may be less optimal as ECM component for CMs in engineered cardiac tissues, it is well possible that collagens may be more appropriate for cardiac tissue engineering based on cardiac expression of ECM proteins. However, in contrast to cardiac tissues with fibrin as scaffold, cardiac tissues with collagen require at least 25% of non-CMs (Mannhardt et al., 2015). The majority of non-CMs in the heart are cardiac fibroblasts which play a key role in the production and remodeling of cardiac ECM proteins, including collagen I and III, fibronectin and laminin (Castaldo et al., 2013). Importantly, in scaffold-free cardiac tissues, only co-culture with adult cardiac fibroblasts, but not fibroblasts of dermal origin, successfully improved CM maturity, as evidenced by enhanced calcium signaling and amended contractile response to inotropic agents (Ravenscroft et al., 2016). This indicates that the origin of cells plays an important role for proper CM function and suggests that co-culture with cardiac cells such as endothelial cells, smooth muscle cells and fibroblasts are required to closely mimic the native cardiac environment and induce CMs maturity. While the co-culture of hPSC-CMs with irradiated human foreskin fibroblasts or hPSC-derived fibroblasts yielded synchronously contracting engineered cardiac tissues based on collagen I in combination with matrigel (Kensah et al., 2013; Thavandiran et al., 2013), only treatment of hPSC-CMs with ascorbic acid in combination with mechanical stimulation yielded some degree of structural maturation with a contraction force of 4.4 mN/mm<sup>2</sup> and a conduction velocity of up to 4.9 cm/s (Kensah et al., 2013); similarly alignment of collagen I and electrical stimulation yielded some aspects of maturation, such as increased transcriptional activity of genes encoding for structural proteins and high conduction velocity (25 cm/s) (Thavandiran et al., 2013).

Not only the presence of fibroblasts, but also endothelial or smooth muscle cells has been demonstrated to advance structural or electrical maturity of hPSC-CMs (Giacomelli et al., 2017; Pasquier et al., 2017; Vuorenpää et al., 2017). However, based on gene expression patterns and morphological characteristics, such as increased cell surface area with well-defined Z discs and nascent intercalated discs, the maturation of hPSC-CMs was only partially accomplished. hPSC-CMs maturity was further enhanced by electrical stimulation as indicated by improved calcium handling. Nonetheless, hPSC-CMs did not develop crosslinking of myosin thick filaments, so-called M-bands, nor t-tubules (Nunes et al., 2013).



Similarly, the inclusion of hPSC-derived vascular endothelial and mural cells (smooth muscle cells and pericytes) into collagen I-matrigel scaffold-based 3D cardiac tissues especially led to structural maturation in hPSC-CMs, which was indicated by organized mitochondria localized between myofibers and enhanced expression of structural proteins, such as  $\beta$ -MHC. Together this led to more organized myofibrillar structure with highly aligned, parallel sarcomeres that demonstrated distinct Z-lines between adjacent sarcomeres, thin filaments (I-bands) and thick filaments (A-bands), but no thick filament crosslinking (M-bands). This resulted in medium force generation (average force 0.62 mN/mm<sup>2</sup>). Despite immature calcium signaling, structural maturation allowed multicellular engineered 3D cardiac tissues to sustain high frequency pacing by maintaining higher active force (Masumoto et al., 2016).

Under defined culture conditions (without matrigel), using a selected cocktail of growth factors, FGF-2, IGF-1, TGF- $\beta$ , and extracellular calcium led to improved CM maturity in collagen I-based 3D cardiac tissues with hPSC-CMs and fibroblasts, as evidenced by increased sarcomeric organization with defined M-bands and a sarcomere size of 1.9  $\mu$ m, yielding a positive force-frequency behavior with a contraction force of 6 mN/mm<sup>2</sup> and N-cadherin-positive intercalated disc-like structures. However, despite some improvement, the transcriptional profile was comparable to fetal heart at 13 weeks of development. Unexpectedly, laminin and fibronectin failed to improve function of 3D cardiac tissues (Tiburcy et al., 2017). Together this indicates that collagen I or fibrin may not be sufficient for mimicking the ECM in order to engineer cardiac tissues *in vitro*.

### Synthetic materials as supportive scaffold in human engineered cardiac tissues

A small range of synthetic materials have been tested as alternative for natural scaffold materials in engineered cardiac tissues from hPSC-CMs. Porous scaffolds engineered from poly(2-hydroxyethyl methacrylate-co-methacrylic acid) (pHEMA-co-MAA) enhanced selected survival and increased proliferation of hPSC-CMs in mixed cardiac tissues, but failed to induce maturity (Madden et al., 2010). Particularly in combination with natural materials, such as collagen, gelatin, matrigel or vitronectin, synthetic

polymers like PEG, PCL, c-PCL, PLGA, polyethylene and PGS successfully supported viability and permitted cell adhesion, spontaneous contraction and also migration of hPSC-CMs *in vitro* or after transplantation *in vivo* (Chen et al., 2010, 2015; Chun et al., 2015; Wang et al., 2013, 2015; Xu et al., 2013). Precisely aligned hPSC-CMs on micropatterned PLGA, coated with gelatin, and matrigel-coated poly-ethylene, exhibited accelerated conduction velocity and reduced predisposition to arrhythmia in optical mappings *in vitro*. Analogous results on PLGA (Chen et al., 2015) and poly-ethylene (Wang et al., 2013) suggest that the decreased sensitivity to arrhythmia can be attributed to the physical alignment of the CMs on micromolded grooves and not the substrate matrix. Interestingly, a co-polymer of 4% PEG and 96% PCL, was able to induce expression of genes attributed to cardiac maturity and improved some functional aspects of cardiac maturation, such as increased expression of structural proteins, isoform switch, mitochondrial function and contractility during *in vitro* culture (Chun et al., 2015).

Synthetic biodegradable, porous PLLA/PLGA scaffolds in combination with matrigel allowed survival and synchronous contraction of hPSC-CMs in engineered 3D human cardiac tissues (Caspi et al., 2007). Importantly, inclusion of endothelial cells into the tissue had an advantageous effect on CM proliferation. However, prominent vascularization occurred only in multicellular tissues with hPSC-CMs, endothelial cells and embryonic fibroblasts. Interestingly, hPSC-CMs within vascularized tissues exhibited features of maturation, such as increased sarcomeric organization and increased functional coupling (Caspi et al., 2007).

PEGylated fibrinogen is a biosynthetic and rapidly biodegradable hydrogel that photo-polymerizes in response to low intensity, long wave UV-light (Almany and Seliktar, 2005; Habib et al., 2011; Shapira-Schweitzer and Seliktar, 2007; Shapira-Schweitzer et al., 2009). Importantly, physical and mechanical properties, such as matrix stiffness, can accurately be regulated by the ratio of synthetic PEG to biological active fibrinogen or the amount of cross linker (Almany and Seliktar, 2005; Habib et al., 2011; Shapira-Schweitzer and Seliktar, 2007; Shapira-Schweitzer et al., 2009). PEGylated fibrinogen hydrogels were the first biosynthetic materials to promote survival and reorganization of isolated neonatal rat CMs, as well as hPSC-CMs into functional contracting tissues without negatively affecting their contractile phenotype even after several weeks (Habib et al., 2011; Shapira-Schweitzer and Seliktar, 2007; Shapira-Schweitzer et al., 2009). Typical



## Chapter 7

response to chronotropic agents, carbamylcholine and the beta-adrenergic agonist isoproterenol, validated responsiveness to cardiac drugs (Shapira-Schweitzer et al., 2009). Engineered cardiac patches with PEGylated fibrinogen as scaffold for hPSC-CMs abridged adverse cardiac remodeling and proved beneficial for ventricular performance post myocardial infarction due to improved fractional shortening (Habib et al., 2011). By preserving contractile function, promoting some features of maturation in hPSC-CMs, PEGylated fibrinogen may serve as promising biosynthetic material for engineering 3D *in vitro* cardiac tissues.

Recent advances in the design of hydrated polymeric hydrogels renders them very useful for mimicking the native ECM environment and controlled tissue engineering either for *in vitro* applications or for *in vivo* tissue regeneration. In general, hydrogels have a high water content, a high biocompatibility and elasticity and consist of either natural materials such as hyaluronic acid, collagen and alginate, or synthetic polymers such as PEG, PVA or PAM. The chemical, mechanical and degradable properties of hydrogels can be modified and biological processes, such as proliferation, differentiation, migration and maturation can be influenced by incorporation and crosslinking of bioactive molecules, indicating the versatile nature of hydrogels. It goes beyond the scope of this review to discuss all the latest developments in hydrogel technology and their possible applications for regenerative medicine and *in vitro* assays. Excellent reviews on this topic have been published elsewhere (Flégeau et al., 2017).

As mentioned before, it has become clear that it is important to mimic the 3D microenvironment of the native cardiac tissue, ensuring dynamic interplay between cardiac cells, ECM components, and bioactive molecules in an optimal structural architecture and topographic organization with appropriate biomechanical (elasticity and stiffness) and electrical conductive properties. Several innovative approaches have been followed in order to generate functional 3D cardiac tissues using engineered 3D fiber-based scaffolds or hydrogel-based. Recently, melting electrowriting, an electrohydrodynamic printing technology, was used to fabricate stretchable microfiber scaffolds with hexagonal microstructures using medical grade polycaprolactone as a polymer. Interestingly, these printed scaffolds supported and enhanced maturation of hPSC-derived CMs. Moreover, these scaffolds were also successfully applied on a beating porcine heart while maintaining their structure (Castilho et al, 2018). Although these hexagonal

structures clearly demonstrated advantages in comparison to rectangular scaffolds, the pores are much larger (approximately 20-fold) than the honeycomb structure of the heart. It remains to be seen whether these scaffolds will support correctly organized multicellular cardiac constructs for optimal cardiac function and intercellular communication.

Another important aspect of cardiac function and maturation is electrical activity. To increase electrical conductivity of biomaterials various polymers have been used, such as polyaniline (PANI), polypyrrole (PYY) and polythiophene as reviewed by Guo and Ma in 2018 (Guo and Ma, 2018). In addition, mixing polymers with graphene or other conductive materials, such as carbon or gold nanoparticles have been shown to increase the electrical conductivity. In addition to their properties related to electrical activation of cardiac tissue, conducting polymers may also have favorable effects on various biological processes. Blending conducting polymers with other polymers like PLA, PLGA and PCL can change biomaterial properties such as degradability, elasticity and stiffness and can also be used in combination with different techniques including electrospinning for the production of ECM-like nanofibers or generation of hydrogels. PPY/PCL and PLA/PANI conductive films or nanofibrous sheets positively affected cardiomyocyte survival, morphology or function *in vitro* (Spearman et al., 2015; Wang et al., 2017) whereas injection of conductive hydrogels encompassing eNOS-expressing nanocomplexes, improved heart function in an experimental model of heart failure (Wang et al., 2018). It will be of interest to study the role of conducting polymers on cardiac function in highly advanced *in vitro* models and *in vivo*.



### **Advanced human cardiac models: towards a pumping mini-heart**

To generate more advanced models more closely resembling cardiac geometry and to allow measurement of hemodynamic cardiac output, Li et al. created for the first time a human ventricle-like cardiac organoid chamber (hvCOC) (Li et al., 2018). In order to achieve this, dissociated hPSC-derived CMs and dermal fibroblasts (for compaction) were reaggreated in the presence of a mixture of collagen I and Matrigel and were transferred to an agarose mold with a centrally placed inflatable balloon, which allowed to form a 3D



human engineered cardiac organoid. HvCOCs were able to pump fluid and ejection fraction and generation of pressure volume loops could be measured in these heart models. Although these results are very promising, cardiac maturation and function may be improved if cardiac fibroblasts will be used instead of dermal fibroblasts (vide supra). MacQueen and colleagues followed another approach to generate a ventricle-like tube (MacQueen et al., 2018). In this study scaffolds were made by pull spinning a mixture of PCL and gelatin onto a mandrel in the shape of an ellipsoidal ventricle. Following sterilization by UV, scaffolds were coated with fibronectin for the attachment of hPSC-derived CMs. Following suturing of the ventricular engineered tissue on a tubing system ejection fraction and pressure volume loops could be measured and were responsive to pharmaceutical compounds. Although it is clear that further improvements are required, it is promising that clinically relevant parameters could be measured in these ventricle-like tubes.

### **Conclusions and future directions**

Although differences in experimental approaches, including timing, origin of cells, use of biomaterials, culture conditions, engineering technologies and endpoint evaluation, make it difficult to directly compare results from different studies, it is evident that the level of cardiomyocyte maturation can be further increased in more advanced 3D tissues when compared to standard monolayer or aggregate differentiation cultures. Nevertheless, even in multicellular 3D cardiac tissues, hPSC-CMs fail to acquire an adult phenotype. So far, little attention has been paid to mimic the native cardiac microenvironment. Instead the majority of cardiac tissues are based on fibrin or collagen I, a matrix which is far from comparable to native cardiac environment, consisting of a complex scaffold of collagen I, III, IV and VI and also laminin, fibronectin, fibrillin and elastin, as well as other components. Temporal and spatial cues from cardiac cells and their microenvironment during human cardiac development (from fetal to adult stages), exemplified by localized and progressive build-up of cardiac ECM components, are essential for a proper understanding of cardiomyocyte maturation. Mimicking the same dynamic stages with gradual assembly of matrix proteins recapitulating cardiac native environment may contribute to maturation of hPSC-CMs *in vitro*, which may be dependent on the self-organization of the engineered cardiac tissue in combination with physical

factors such as mechanical load and electrical stimuli. In this context, it is intriguing to speculate that hPSC-derived cardiac cells, either progenitor cells or functional subtypes, and biomaterials may be positioned in the appropriate architecture by 3D-bioprinting technology. Although many hurdles need to be overcome before vascularized cardiac tissues can be printed (including survival of cells and printing resolution), recent advances have shown the feasibility to generate viable organized tissues (Duan, 2016; Murphy and Atala, 2014). Advances in differentiation, characterization and purification of hPSC-derived cardiac cells along with those in biomaterials, polymers and tissue engineering will facilitate controlled and defined construction of heart tissue, using fetal and adult stages of the human heart as a molecular, morphological and functional blueprint, which undoubtedly has a major impact on regenerative medicine. In addition, with this in prospect, we expect to gain insight to what level of organization and maturation of engineered heart tissues can be achieved *in vitro* and to what extent this will be sufficient to reveal key aspects of cardiac disease using patient-derived hPSCs. With the development of innovative smart hydrogels and other materials new opportunities have arisen for dynamic interaction with cells and tissues in a temporal and spatial manner. In combination with other recent advances in other fields such as microfabrication, nanotechnology, electrical engineering, biosensors, membranes, chemistry, membrane sciences, 3D printing, etc., new opportunities have been created to mimic tissue or organ function in small (normally micrometre- or millimetre-sized) chambers or chip-like devices. In these so-called “organs-on-chips” the microenvironment can be controlled and biological and functional readouts can be implemented in a flexible and multiplex manner. Increased understanding of how ECM components and synthetic polymers affect biological responses and function under physiological and pathophysiological conditions, will facilitate development of predictable human *in vitro* models for safety pharmacology and drug discovery and generation of multicellular tissue constructs for clinical use.



## **Acknowledgements**

We would like to thank Aisen De sa Vivas for critical reading of the document and Christian B Schwach for illustrations.

## References

- Alings, A.M., Abbas, R.F., and Bouman, L.N. (1995). Age-related changes in structure and relative collagen content of the human and feline sinoatrial node. A comparative study. *Eur. Heart J.* 16, 1655–1667.
- Almany, L., and Seliktar, D. (2005). Biosynthetic hydrogel scaffolds made from fibrinogen and polyethylene glycol for 3D cell cultures. *Biomaterials* 26, 2467–2477.
- Bashey, R.I., Martinez-Hernandez, A., and Jimenez, S.A. (1992). Isolation, Characterization, and Localization of Cardiac Collagen Type VI Associations With Other Extracellular Matrix Components. *Circ. Reserch* 70, 1006–1017.
- van den Berg, C.W., Okawa, S., Chuva de Sousa Lopes, S.M., van Iperen, L., Passier, R., Braam, S.R., Tertoolen, L.G., Del Sol, A., Davis, R.P., and Mummery, C.L. (2015). Transcriptome of human foetal heart compared with cardiomyocytes from pluripotent stem cells. *Development* 3231–3238.
- Birket, M.J., Ribeiro, M.C., Verkerk, A.O., Ward, D., Leitoguinho, A.R., den Hartogh, S.C., Orlova, V. V, Devalla, H.D., Schwach, V., Bellin, M., et al. (2015). Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells. *Nat. Biotechnol.* 1–12.
- Bishop, J.E., and Laurent, G.J. (1995). Collagen turnover and its regulation in the normal and hypertrophying heart. *Eur. Heart J.* 16 Suppl C, 38–44.
- Bishop, J.E., Greenbaum, R., Gibson, D.G., Yacoub, M., and Laurent, G.J. (1990). Enhanced deposition of predominantly type I collagen in myocardial disease. *J. Mol. Cell. Cardiol.* 22, 1157–1165.
- Boldt, A., Wetzel, U., Lauschke, J., Weigl, J., Gummert, J., Hindricks, G., Kottkamp, H., and Dhein, S. (2004). Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. *Heart* 90, 400–405.
- Borg, T.K., Gay, R.E., and Johnson, L.D. (1982). Changes in the distribution of fibronectin and collagen during development of the neonatal rat heart. *Collagen Rel. Res* 2, 211–218.
- Braam, S.R., Tertoolen, L., van de Stolpe, A., Meyer, T., Passier, R., and Mummery, C.L. (2010). Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. *Stem Cell Res.* 4, 107–116.
- Burridge, P.W., Matsa, E., Shukla, P., Lin, Z.C., Churko, J.M., Ebert, A.D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N.M., et al. (2014). Chemically defined generation of human cardiomyocytes. *Nat. Methods* 11, 855–860.
- de Carvalho Filho, E.T., de Carvalho, C.A., and de Souza, R.R. (1996). Age-related changes in elastic fibers of human heart. *Gerontology* 42, 211–217.
- Caspi, O., Lesman, A., Basevitch, Y., Gepstein, A., Arbel, G., Huber, I., Habib, M., Gepstein, L., and Levenberg, S. (2007). Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. *Circ. Res.* 100, 263–272.
- Caspi, O., Itzhaki, I., Kehat, I., Gepstein, A., Arbel, G., Huber, I., Satin, J., and Gepstein, L. (2009). *In vitro* electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. *Stem Cells Dev.* 18, 161–172.
- Castaldo, C., Di Meglio, F., Miraglia, R., Sacco, A.M., Romano, V., Banccone, C., Della Corte, A., Montagnani, S., and Nurzynska, D. (2013). Cardiac fibroblast-derived extracellular matrix (biomatrix) as a model for the studies of cardiac primitive cell biological properties in normal and pathological adult human heart. *Biomed Res. Int.* 2013.
- Castilho, M., Feyen, D., Flandes-Iparraguirre, M., Hochleitner, G., Groll, J., Doevendans, P.A.F., Vermonden, T., Ito, K., Sluijter, J.P.G., and Malda, J. (2017). Melt Electrospinning Writing of Poly-Hydroxymethylglycolide-co-ε-Caprolactone-Based Scaffolds for Cardiac Tissue Engineering. *Adv. Healthc. Mater.* 6, 1–9.
- Chen, A., Lee, E., Tu, R., Santiago, K., Grosberg, A., Fowlkes, C., and Khine, M. (2014). Integrated platform for functional monitoring of biomimetic heart sheets derived from human pluripotent stem cells. *Biomaterials* 35, 675–683.
- Chen, Q.Z., Ishii, H., Thouas, G.A., Lyon, A.R., Wright, J.S., Blaker, J.J., Chrzanowski, W., Boccaccini, A.R., Ali, N.N., Knowles, J.C., et al. (2010). An elastomeric patch derived from poly(glycerol sebacate) for delivery of embryonic stem cells to the heart. *Biomaterials* 31, 3885–3893.
- Chen, Y., Wang, J., Shen, B., Chan, C.W.Y., Wang, C., Zhao, Y., Chan, H.N., Tian, Q., Chen, Y., Yao, C., et al. (2015). Engineering a freestanding biomimetic cardiac patch using biodegradable poly(lactic-co-glycolic acid) (PLGA) and human embryonic stem cell-derived ventricular cardiomyocytes (hESC-VCMs). *Macromol. Biosci.* 15, 426–436.
- Chong, J.J.H., Yang, X., Don, C.W., Minami, E., Liu, Y.-W., Weyers, J.J., Mahoney, W.M.,

## Chapter 7

- Van Biber, B., Cook, S.M., Palpant, N.J., et al. (2014). Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. *Nature* 510, 273–277.
- Chun, Y.W., Balikov, D. a, Feaster, T.K., Williams, C.H., Sheng, C.C., Lee, J.-B., Boire, T.C., Neely, M.D., Bellan, L.M., Ess, K.C., et al. (2015). Combinatorial polymer matrices enhance *in vitro* maturation of human induced pluripotent stem cell-derived cardiomyocytes. *Biomaterials* 67, 52–64.
- Csepe, T.A., Kalyanasundaram, A., Hansen, B.J., Zhao, J., and Fedorov, V. V. (2015). Fibrosis: A structural modulator of sinoatrial node physiology and dysfunction. *Front. Physiol.* 6, 1–8.
- Denning, C., Borgdorff, V., Crutchley, J., Firth, K.S.A., George, V., Kalra, S., Kondrashov, A., Hoang, M.D., Mosqueira, D., Patel, A., et al. (2016). Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. *Biochim. Biophys. Acta - Mol. Cell Res.* 1863, 1728–1748.
- Devalla, H.D., Schwach, V., Ford, J.W., Milnes, J.T., El-Haou, S., Jackson, C., Gkatzis, K., Elliott, D.A., Chuvp de Sousa Lopes, S.M., Mummery, C.L., et al. (2015). Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. *EMBO Mol. Med.* 7, 394–410.
- Doherty, K.R., Talbert, D.R., Trusk, P.B., Moran, D.M., Shell, S.A., and Bacus, S. (2015). Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types. *Toxicol. Appl. Pharmacol.* 285, 51–60.
- Duan, B. (2016). State-of-the-Art Review of 3D Bioprinting for Cardiovascular Tissue Engineering. *Ann. Biomed. Eng.*
- Farhadian, F., Contard, F., Sabri, A., Samuel, J.L., and Rappaport, L. (1996). Fibronectin and basement membrane in cardiovascular organogenesis and disease pathogenesis. *Cardiovasc. Res.* 32, 433–442.
- Farouz, Y., Chen, Y., Terzic, A., and Menasche, P. (2015). Concise review: Growing hearts in the right place: On the design of biomimetic materials for cardiac stem cell differentiation. *Stem Cells* 33, 1021–1035.
- Flégeau, K., Pace, R., Gautier, H., Rethore, G., Guicheux, J., Le Visage, C., and Weiss, P. (2017). Toward the development of biomimetic injectable and macroporous biohydrogels for regenerative medicine. *Adv. Colloid Interface Sci.* 247, 589–609.
- Gazoti Debessa, C.R., Mesiano Maifrino, L.B., and Rodrigues de Souza, R. (2001). Age related changes of the collagen network of the human heart. *Mech. Ageing Dev.* 122, 1049–1058.
- Giacomelli, E., Bellin, M., Sala, L., van Meer, B.J., Tertoolen, L.G.J., Orlova, V. V., and Mummery, C.L. (2017). Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells. *Development* dev.143438.
- Guadix, J.A., Orlova, V. V., Giacomelli, E., Bellin, M., Ribeiro, M.C., Mummery, C.L., Pérez-Pomares, J.M., and Passier, R. (2017). Human Pluripotent Stem Cell Differentiation into Functional Epicardial Progenitor Cells. *Stem Cell Reports* 9, 1754–1764.
- Guo, B., and Ma, P.X. (2018). Conducting Polymers for Tissue Engineering. *Biomacromolecules* 19, 1764–1782.
- Habib, M., Shapira-Schweitzer, K., Caspi, O., Gepstein, A., Arbel, G., Aronson, D., Seliktar, D., and Gepstein, L. (2011). A combined cell therapy and in-situ tissue-engineering approach for myocardial repair. *Biomaterials* 32, 7514–7523.
- Heras-Bautista, C.O., Katsen-Globa, A., Schloerer, N.E., Dieluweit, S., Abd El Aziz, O.M., Peinkofer, G., Attia, W.A., Khalil, M., Brockmeier, K., Hescheler, J., et al. (2014). The influence of physiological matrix conditions on permanent culture of induced pluripotent stem cell-derived cardiomyocytes. *Biomaterials* 35, 7374–7385.
- Himmel, H.M. (2013). Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds. *J. Pharmacol. Toxicol. Methods* 68, 97–111.
- Hirt, M.N., Boeddinghaus, J., Mitchell, A., Schaaf, S., Börnchen, C., Müller, C., Schulz, H., Hubner, N., Stenzig, J., Stoehr, A., et al. (2014). Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. *J. Mol. Cell. Cardiol.* 74, 151–161.
- Iyer, D., Gambardella, L., Bernard, W.G., Serrano, F., Mascetti, V.L., Pedersen, R. a, Talasila, A., and Sinha, S. (2015). Robust derivation of epicardium and its differentiated smooth muscle cell progeny from human pluripotent stem cells. *Development* 142, 1528–1541.
- Jackson, M., Connell, M.G., and Smith, A. (1993). Development of the collagen network of the human fetal myocardium: an immunohistochemical study. *Int. J. Cardiol.* 41, 77–86.
- James, T.N. (1970). Cardiac conduction system: fetal and postnatal development. *Am. J.*

Cardiol. 25, 213–226.

Jiang, Y.-Y., Yang, Q., Liu, X.-C., and He, G.-W. (2016). Mechanism of Atrial Fibrillation is Related to Changes of Type IV Collagen in Rheumatic Heart Valvular Disease. FASEB J. Abstract.

Kapelko, V.I. (2001). Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form. Exp. Clin. Cardiol. 6, 41–49.

Kensah, G., Lara, A.R., Dahlmann, J., Zweigerdt, R., Schwanke, K., Hegermann, J., Skvorc, D., Gawol, A., Azizian, A., Wagner, S., et al. (2013). Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue *in vitro*. Eur. Heart J. 34, 1134–1146.

Kim, H., Yoon, C.S., Kim, H., and Rah, B.-J. (1999). Expression of extracellular matrix components fibronectin and laminin in the human fetal heart. Cell Struct. Funct. 24, 19–26.

Kitamura, M., Shimizu, M., Ino, H., Okeie, K., Yamaguchi, M., Funjino, N., Mabuchi, H., and Nakanishi, I. (2001). Collagen remodeling and cardiac dysfunction in patients with hypertrophic cardiomyopathy: the significance of type III and VI collagens. Clin. Cardiol. 24, 325–329.

Kléber, A.G., and Rudy, Y. (2004). Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol. Rev. 84, 431–488.

van Laake, L.W., Passier, R., Monshouwer-Kloots, J., Verkleij, A.J., Lips, D.J., Freund, C., den Ouden, K., Ward-van Oostwaard, D., Korving, J., Tertoolen, L.G., et al. (2007). Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 1, 9–24.

Laflamme, M. a, Chen, K.Y., Naumova, A. V, Muskheli, V., Fugate, J. a, Dupras, S.K., Reinecke, H., Xu, C., Hassanipour, M., Police, S., et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25, 1015–1024.

Laksman, Z., Wauchop, M., Lin, E., Protze, S., Lee, J., Yang, W., Izaddoustdar, F., Shafaattalab, S., Gepstein, L., Tibbits, G.F., et al. (2017). Modeling Atrial Fibrillation using Human Embryonic Stem Cell-Derived Atrial Tissue. Sci. Rep. 7, 1–11.

Legate, K.R., Wickström, S. a, Fässler, R., Fa, R., and Wickstro, S. a (2009). Genetic and cell biological analysis of integrin outside-in signaling Genetic and cell biological analysis of integrin outside-in signaling. 397–418.

Li, R.A., Keung, W., Cashman, T.J., Backeris, P.C., Johnson, B. V., Bardot, E.S., Wong, A.O.T., Chan, P.K.W., Chan, C.W.Y., and Costa, K.D. (2018). Bioengineering an electromechanically functional miniature ventricular heart chamber from human pluripotent stem cells. Biomaterials 163, 116–127.

Liang, H., Matzkies, M., Schunkert, H., Tang, M., Bonnemeier, H., Hescheler, J., and Reppel, M. (2010). Human and murine embryonic stem cell-derived cardiomyocytes serve together as a valuable model for drug safety screening. Cell. Physiol. Biochem. 25, 459–466.

Liang, P., Lan, F., Lee, A.S., Gong, T., Sanchez-Freire, V., Wang, Y., Diecke, S., Sallam, K., Knowles, J.W., Wang, P.J., et al. (2013). Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127, 1677–1691.

Lombardi, R., Betocchi, S., Losi, M.A., Tocchetti, C.G., Aversa, M., Miranda, M., D'Alessandro, G., Cacace, A., Ciampi, Q., and Chiariello, M. (2003). Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation 108, 1455–1460.

Lu, F., Ma, F.F., Zhang, W., Li, Y., Wei, F.Y., and Zhou, L. (2015). Qualitative research of alternatively splice variants of fibronectin in different development stage of mice heart. J. Thorac. Dis. 7, 2307–2312.

Lu, T.-Y., Lin, B., Kim, J., Sullivan, M., Tobita, K., Salama, G., and Yang, L. (2013). Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. Nat. Commun. 4, 2307.

Ma, Y., De Castro Brás, L.E., Toba, H., Iyer, R.P., Hall, M.E., Winniford, M.D., Lange, R.A., Tyagi, S.C., and Lindsey, M.L. (2014). Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch. Eur. J. Physiol. 466, 1113–1127.

MacQueen, L.A., Sheehy, S.P., Chantre, C.O., Zimmerman, J.F., Pasqualini, F.S., Liu, X., Goss, J.A., Campbell, P.H., Gonzalez, G.M., Park, S.J., et al. (2018). A tissue-engineered scale model of the heart ventricle. Nat. Biomed. Eng.

Madden, L.R., Mortisen, D.J., Sussman, E.M., Dupras, S.K., Fugate, J.A., Cuy, J.L., Hauch, K.D., Laflamme, M.A., Murray, C.E., and Ratner, B.D. (2010). Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc. Natl. Acad. Sci. U. S. A. 107, 15211–15216.

Mannhardt, I., Breckwoldt, K., Letuffe-Brenière, D., Schaaf, S., Schulz, H., Neuber, C., Benzin, A., Werner, T., Eder, A., Schulze, T., et al. (2015). Human Engineered Heart Tissue: Analysis of



## Chapter 7

Contractile Force. *Stem Cell Reports* 7, 29–42.

Marijjanowski, M.M.H., van der Loos, C.M., Mohrschladt, M.F., and Becker, A.E. (1994). The neonatal heart has a relatively high content of total collagen and type I collagen, a condition that may explain the less compliant state. *J. Am. Coll. Cardiol.* 23, 1204–1208.

Masuda, H. and Smcujo, S. (1981). Isolation and characterization of glycosaminoglycans from atria of the human heart. *Int. J. Biochem.* 13, 603–608.

Masumoto, H., Nakane, T., Tinney, J.P., Yuan, F., Ye, F., Kowalski, W.J., Minakata, K., Sakata, R., Yamashita, J.K., and Keller, B.B. (2016). The myocardial regenerative potential of three-dimensional engineered cardiac tissues composed of multiple human iPSC cell-derived cardiovascular cell lineages. *Sci. Rep.* 6, 29933.

McCain, M.L., Agarwal, A., Nesmith, H.W., Nesmith, A.P., and Parker, K.K. (2014). Micromolded gelatin hydrogels for extended culture of engineered cardiac tissues. *Biomaterials* 35, 5462–5471.

Mittal, A., Pulina, M., Hou, S.Y., and Astrof, S. (2013). Fibronectin and integrin alpha 5 play requisite roles in cardiac morphogenesis. *Dev. Biol.* 381, 73–82.

Mummery, C., Zhang, J., Ng, E., Elliott, D., Elefanty, A.G., and Kamp, T.J. (2012). Differentiation of Human ES and iPSC Cells to Cardiomyocytes: A Methods Overview. *Circ Res* 111, 344–358.

Murphy, S. V., and Atala, A. (2014). 3D Bioprinting of Tissues and Organs. *Nat. Biotechnol.* 32, 773–785.

Nabipour, A. (2012). Comparative histological structure of the sinus node in mammals. *Turkish J. Vet. Anim. Sci.* 36, 463–469.

Nakane, T., Masumoto, H., Tinney, J.P., Yuan, F., Kowalski, W.J., Ye, F., LeBlanc, A.J., Sakata, R., Yamashita, J.K., and Keller, B.B. (2017). Impact of Cell Composition and Geometry on Human Induced Pluripotent Stem Cells-Derived Engineered Cardiac Tissue. *Sci. Rep.* 7, 45641.

Navarrete, E.G., Liang, P., Lan, F., Sanchez-Freire, V., Simmons, C., Gong, T., Sharma, A., Burridge, P.W., Patlolla, B., Lee, A.S., et al. (2013). Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. *Circulation* 128.

Nunes, S.S., Miklas, J.W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Massé, S., Gagliardi, M., Hsieh, A., et al. (2013). Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. *Nat. Methods* 10, 781–787.

O'Brien, F.J. (2011). Biomaterials & scaffolds for tissue engineering. *Mater. Today* 14, 88–95.

Oken, D.E., and Boucek, R.J. (1957). Quantitation of Collagen in Human Myocardium. *Circ. Res.* 5, 357–361.

Oliviero, P., Chassagne, C., Salichon, N., Corbier, A., Hamon, G., Marotte, F., Charlemagne, D., Rappaport, L., and Samuel, J.L. (2000). Expression of laminin  $\alpha 2$  chain during normal and pathological growth of myocardium in rat and human. *Cardiovasc. Res.* 46, 346–355.

Orlova, V. V., van den Hil, F.E., Petrus-Reurer, S., Drabsch, Y., Ten Dijke, P., and Mummery, C.L. (2014). Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells. *Nat. Protoc.* 9, 1514–1531.

Pasquier, J., Gupta, R., Rioult, D., Hoarau-Véhot, J., Courjaret, R., Machaca, K., Al Suwaidi, J., Stanley, E.G., Rafii, S., Elliott, D.A., et al. (2017). Coculturing with endothelial cells promotes *in vitro* maturation and electrical coupling of human embryonic stem cell-derived cardiomyocytes. *J. Hear. Lung Transplant.*

Patel, A.K., Celiz, A.D., Rajamohan, D., Anderson, D.G., Langer, R., Davies, M.C., Alexander, M.R., and Denning, C. (2015). A defined synthetic substrate for serum free culture of human stem cell derived cardiomyocytes with improved functional maturity identified using combinatorial materials microarrays. *Biomaterials* 61, 257–265.

Pauschinger, M., Knopf, D., Petschauer, S., Doerner, a, Poller, W., Schwimmbeck, P.L., Kühl, U., and Schultheiss, H.P. (1999). Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. *Circulation* 99, 2750–2756.

Pei, F., Jiang, J., Bai, S., Cao, H., Tian, L., Zhao, Y., Yang, C., Dong, H., and Ma, Y. (2017). Chemical-defined and albumin-free generation of human atrial and ventricular myocytes from human pluripotent stem cells. *Stem Cell Res.* 19, 94–103.

Protze, S.I., Liu, J., Nussinovitch, U., Ohana, L., Backx, P.H., Gepstein, L., and Keller, G.M. (2016). Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker. *Nat. Biotechnol.* 35, 1–16.

Ravenscroft, S.M., Pointon, A., Williams, A.W., Cross, M.J., and Sidaway, J.E. (2016). Cardiac Non-myocyte Cells Show Enhanced Pharmacological Function Suggestive of Contractile Maturity in Stem Cell Derived Cardiomyocyte Microtissues. *Toxicol. Sci.* 152, kfw069.

Ribeiro, M.C., Tertoolen, L.G., Guadix, J. a., Bellin, M., Kosmidis, G., D'Aniello, C., Monshouwer-

- Kloots, J., Goumans, M.-J., Wang, Y., Feinberg, A.W., et al. (2015). Functional maturation of human pluripotent stem cell derived cardiomyocytes *in vitro* – Correlation between contraction force and electrophysiology. *Biomaterials* 51, 138–150.
- Rienks, M., Papageorgiou, A.P., Frangogiannis, N.G., and Heymans, S. (2014). Myocardial extracellular matrix: An ever-changing and diverse entity. *Circ. Res.* 114, 872–888.
- Robertson, C., Tran, D.D., and George, S.C. (2013). Concise review: Maturation phases of human pluripotent stem cell-derived cardiomyocytes. *Stem Cells* 31, 829–837.
- Ronaldson, K., Ma, S., Yeager, K., Chen, T., Song, L., and Sirabella, D. (2018). Advanced maturation of human cardiac tissue grown from pluripotent stem cells. *Nature*.
- Saetersdal, T., Larsen, T., Rotevatn, S., Dalen, H., and Scheie, P. (1992). Fibronectin and laminin in transverse tubules of cardiac myocytes studied by laser confocal microscopy and immunocytochemistry. *Histochemistry* 98, 73–80.
- Schaaf, S., Shibamiya, A., Mewe, M., Eder, A., Stoehr, A., Hirt, M.N., Rau, T., Zimmermann, W.-H., Conradi, L., Eschenhagen, T., et al. (2011). Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. *PLoS One* 6.
- Schwach, V., Verkerk, A.O., Mol, M., Monshouwer-Kloots, J.J., Devalla, H.D., Orlova, V. V., Anastassiadis, K., Mummery, C.L., Davis, R.P., and Passier, R. (2017). A COUP-TFII Human Embryonic Stem Cell Reporter Line to Identify and Select Atrial Cardiomyocytes. *Stem Cell Reports* 9, 1–15.
- Shapira-Schweitzer, K., and Seliktar, D. (2007). Matrix stiffness affects spontaneous contraction of cardiomyocytes cultured within a PEGylated fibrinogen biomaterial. *Acta Biomater.* 3, 33–41.
- Shapira-Schweitzer, K., Habib, M., Gepstein, L., and Seliktar, D. (2009). A photopolymerizable hydrogel for 3-D culture of human embryonic stem cell-derived cardiomyocytes and rat neonatal cardiac cells. *J. Mol. Cell. Cardiol.* 46, 213–224.
- Sharma, A., Marceau, C., Hamaguchi, R., Burridge, P.W., Rajarajan, K., Churko, J.M., Wu, H., Sallam, K.I., Matsa, E., Sturzu, A.C., et al. (2014). Human induced pluripotent stem cell-derived cardiomyocytes as an *in vitro* model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform. *Circ. Res.* 115, 556–566.
- Shen, B., Delaney, M.K., and Du, X. (2012). Inside-out, outside-in, and inside-outside-in: G protein signaling in integrin-mediated cell adhesion, spreading, and retraction. *Curr. Opin. Cell Biol.* 24, 600–606.
- Shiba, Y., Gomibuchi, T., Seto, T., Wada, Y., Ichimura, H., Tanaka, Y., Ogasawara, T., Okada, K., Shiba, N., Sakamoto, K., et al. (2016). Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. *Nature* 538, 388–391.
- Shichijo, S., and Masuda, H. (1980). Isolation and characterization of glycosaminoglycans from ventricles of the human heart. *Biochem. Med.* 23, 150–158.
- Shinozawa, T., Imahashi, K., Sawada, H., Furukawa, H., and Takami, K. (2012). Determination of Appropriate Stage of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Screening and Pharmacological Evaluation *In vitro*. *J. Biomol. Screen.* 17, 1192–1203.
- Smorodinova, N., Lantová, L., Bláha, M., Melenovský, V., Hanzelka, J., Pirk, J., Kautzner, J., and Kučera, T. (2015). Bioptic Study of Left and Right Atrial Interstitium in Cardiac Patients with and without Atrial Fibrillation: Interatrial but Not Rhythm-Based Differences. *PLoS One* 10, e0129124.
- de Souza, R.R. (2002). Aging of myocardial collagen. *Biogerontology* 3, 325–335.
- Spearman, B.S., Hodge, A.J., Porter, J.L., Hardy, J.G., Davis, Z.D., Xu, T., Zhang, X., Schmidt, C.E., Hamilton, M.C., and Lipke, E.A. (2015). Conductive interpenetrating networks of polypyrrole and polycaprolactone encourage electrophysiological development of cardiac cells. *Acta Biomater.* 28, 109–120.
- Speiser, B., Riess, C., and Schaper, J. (1991). The extracellular matrix in human myocardium: Part I: Collagens I, III, IV, and VI. *Cardioscience*.
- Speiser, B., Weihrauch, D., Riess, C., and Schaper, J. (1992). The extracellular matrix in human cardiac tissue. Part II: Vimentin, laminin, and fibronectin. *Cardioscience*.
- Stancescu, M., Molnar, P., McAleer, C.W., McLamb, W., Long, C.J., Oleaga, C., Prot, J.-M., and Hickman, J.J. (2015). A phenotypic *in vitro* model for the main determinants of human whole heart function. *Biomaterials* 60, 20–30.
- Stec, J.J., Silbershatz, H., Tofler, G.H., Matheney, T.H., Sutherland, P., Lipinska, I., Massaro, J.M., Wilson, P.F., Muller, J.E., and D’Agostino, R.B. (2000). Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. *Circulation* 102, 1634–1638.
- Stoehr, A., Neuber, C., Baldauf, C., Vollert, I., Friedrich, F.W., Flenner, F., Carrier, L., Eder, A., Schaaf, S., Hirt, M.N., et al. (2014). Automated analysis of contractile force and Ca<sup>2+</sup> transients





## Chapter 7

- in engineered heart tissue. *Am. J. Physiol. Heart Circ. Physiol.* 306, H1353-63.
- Sun, X., and Nunes, S.S. (2017). Bioengineering Approaches to Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes. *Front. Cell Dev. Biol.* 5, 19.
- Talbert, D.R., Doherty, K.R., Trusk, P.B., Moran, D.M., Shell, S.A., and Bacus, S. (2015). A multi-parameter *in vitro* screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. *Toxicol. Sci.* 143, 147-155.
- Thavandiran, N., Dubois, N., Mikryukov, A., Massé, S., Simmons, C.A., Deshpande, V.S., Patrick, J., Chen, C.S., Nanthakumar, K., Keller, G.M., et al. (2013). Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. *Proc. Natl. Acad. Sci.* 111, 16973.
- Tiburcy, M., Hudson, J.E., Balfanz, P., Schlick, S.F., Meyer, T., Chang Liao, M.-L., Levent, E., Raad, F., Zeidler, S., Wingender, E., et al. (2017). Defined Engineered Human Myocardium with Advanced Maturation for Applications in Heart Failure Modelling and Repair. *Circulation*.
- Veerman, C.C., Kosmidis, G., Mummery, C.L., Casini, S., Verkerk, A.O., and Bellin, M. (2015). Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? *Stem Cells Dev.* 24, 1035-1052.
- Votteler, M., Berrio, D. a C., Horke, A., Sabatier, L., Reinhardt, D.P., Nsair, A., Aikawa, E., and Schenke-Layland, K. (2013). Elastogenesis at the onset of human cardiac valve development. *Development* 140, 2345-2353.
- Vuorenää, H., Penttinen, K., Heinonen, T., Pekkanen-Mattila, M., Sarkanen, J.-R., Ylikomi, T., and Aalto-Setälä, K. (2017). Maturation of human pluripotent stem cell derived cardiomyocytes is improved in cardiovascular construct. *Cytotechnology*.
- Wang, J., Chen, A., Lieu, D.K., Karakikes, I., Chen, G., Keung, W., Chan, C.W., Hajjar, R.J., Costa, K.D., Khine, M., et al. (2013). Effect of engineered anisotropy on the susceptibility of human pluripotent stem cell-derived ventricular cardiomyocytes to arrhythmias. *Biomaterials* 34, 8878-8886.
- Wang, L., Wua, Y., Hu, Tianli, B., Guo, B., and Ma, P.X. (2017). Electrospun conductive nanofibrous scaffolds for engineering cardiac tissue and 3D bioactuators. *Acta Biomater. J.* 59, 69-81.
- Wang, W., Tan, B., Chen, J., Bao, R., Zhang, X., Liang, S., Shang, Y., Liang, W., Cui, Y., Fan, G., et al. (2018). An injectable conductive hydrogel encapsulating plasmid DNA-eNOs and ADSCs for treating myocardial infarction. *Biomaterials* 160, 69-81.
- Wang, X., Chun, Y.W., Zhong, L., Chiusa, M., Balikov, D.A., Frist, A.Y., Lim, C.C., Maltais, S., Bellan, L., Hong, C.C., et al. (2015). A temperature-sensitive, self-adhesive hydrogel to deliver iPSC-derived cardiomyocytes for heart repair. *Int. J. Cardiol.* 190, 177-180.
- Witty, A.D., Mihic, A., Tam, R.Y., Fisher, S.A., Mikryukov, A., Shoichet, M.S., Li, R.-K., Kattman, S.J., and Keller, G. (2014). Generation of the epicardial lineage from human pluripotent stem cells. *Nat. Biotechnol.* 32, 1026-1035.
- Xu, B., Li, Y., Fang, X., Thouas, G.A., Cook, W.D., Newgreen, D.F., and Chen, Q. (2013). Mechanically tissue-like elastomeric polymers and their potential as a vehicle to deliver functional cardiomyocytes. *J. Mech. Behav. Biomed. Mater.* 28, 354-365.
- Yang, X., Pabon, L., and Murry, C.E. (2014). Engineering Adolescence: Maturation of Human Pluripotent Stem Cell-derived Cardiomyocytes. *Circ. Res.* 114, 511-523.
- Yanni, J., Tellez, J.O., Sutyagin, P. V., Boyett, M.R., and Dobrzynski, H. (2010). Structural remodelling of the sinoatrial node in obese old rats. *J. Mol. Cell. Cardiol.* 48, 653-662.
- Zhang, D., Shadrin, I.Y., Lam, J., Xian, H.Q., Snodgrass, H.R., and Bursac, N. (2013). Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. *Biomaterials* 34, 5813-5820.
- Zhang, W., Kong, C.W., Tong, M.H., Chooi, W.H., Huang, N., Li, R.A., and Chan, B.P. (2017). Maturation of human embryonic stem cell-derived cardiomyocytes (hESC-CMs) in 3D collagen matrix: Effects of niche cell supplementation and mechanical stimulation. *Acta Biomater.* 49, 204-217.

